BACKGROUND: The extent of surgery for papillary thyroid cancers (PTC) remains controversial. Consensus guidelines have recommended total thyroidectomy for PTC > or =1 cm; however, no study has supported this recommendation based on a survival advantage. The objective of this study was to examine whether the extent of surgery affects outcomes for PTC and to determine whether a size threshold could be identified above which total thyroidectomy is associated with improved outcomes. METHODS: From the National Cancer Data Base (1985-1998), 52,173 patients underwent surgery for PTC. Survival was estimated by the Kaplan-Meier method and compared using log-rank tests. Cox Proportional Hazards modeling stratified by tumor size was used to assess the impact of surgical extent on outcomes and to identify a tumor size threshold above which total thyroidectomy is associated with an improvement in recurrence and long-term survival rates. RESULTS: Of the 52,173 patients, 43,227 (82.9%) underwent total thyroidectomy, and 8946 (17.1%) underwent lobectomy. For PTC <1 cm extent of surgery did not impact recurrence or survival (P = 0.24, P = 0.83). For tumors > or =1 cm, lobectomy resulted in higher risk of recurrence and death (P = 0.04, P = 0.009). To minimize the influence of larger tumors, 1 to 2 cm lesions were examined separately: lobectomy again resulted in a higher risk of recurrence and death (P = 0.04, P = 0.04). CONCLUSIONS: The results of this study demonstrate that total thyroidectomy results in lower recurrence rates and improved survival for PTC > or =1.0 cm compared with lobectomy. This is the first study to demonstrate that total thyroidectomy for PTC > or =1.0 cm improves outcomes.
BACKGROUND: The extent of surgery for papillary thyroid cancers (PTC) remains controversial. Consensus guidelines have recommended total thyroidectomy for PTC > or =1 cm; however, no study has supported this recommendation based on a survival advantage. The objective of this study was to examine whether the extent of surgery affects outcomes for PTC and to determine whether a size threshold could be identified above which total thyroidectomy is associated with improved outcomes. METHODS: From the National Cancer Data Base (1985-1998), 52,173 patients underwent surgery for PTC. Survival was estimated by the Kaplan-Meier method and compared using log-rank tests. Cox Proportional Hazards modeling stratified by tumor size was used to assess the impact of surgical extent on outcomes and to identify a tumor size threshold above which total thyroidectomy is associated with an improvement in recurrence and long-term survival rates. RESULTS: Of the 52,173 patients, 43,227 (82.9%) underwent total thyroidectomy, and 8946 (17.1%) underwent lobectomy. For PTC <1 cm extent of surgery did not impact recurrence or survival (P = 0.24, P = 0.83). For tumors > or =1 cm, lobectomy resulted in higher risk of recurrence and death (P = 0.04, P = 0.009). To minimize the influence of larger tumors, 1 to 2 cm lesions were examined separately: lobectomy again resulted in a higher risk of recurrence and death (P = 0.04, P = 0.04). CONCLUSIONS: The results of this study demonstrate that total thyroidectomy results in lower recurrence rates and improved survival for PTC > or =1.0 cm compared with lobectomy. This is the first study to demonstrate that total thyroidectomy for PTC > or =1.0 cm improves outcomes.
Authors: R H Cobin; H Gharib; D A Bergman; O H Clark; D S Cooper; G H Daniels; R A Dickey; D S Duick; J R Garber; I D Hay; J S Kukora; H M Lando; A B Schorr; M A Zeiger Journal: Endocr Pract Date: 2001 May-Jun Impact factor: 3.443
Authors: Jacqueline Jonklaas; Nicholas J Sarlis; Danielle Litofsky; Kenneth B Ain; S Thomas Bigos; James D Brierley; David S Cooper; Bryan R Haugen; Paul W Ladenson; James Magner; Jacob Robbins; Douglas S Ross; Monica Skarulis; Harry R Maxon; Steven I Sherman Journal: Thyroid Date: 2006-12 Impact factor: 6.568
Authors: John Z Ayanian; Alan M Zaslavsky; Charles S Fuchs; Edward Guadagnoli; Cynthia M Creech; Rosemary D Cress; Lilia C O'Connor; Dee W West; Mark E Allen; Robert E Wolf; William E Wright Journal: J Clin Oncol Date: 2003-04-01 Impact factor: 44.544
Authors: Rosemary D Cress; Alan M Zaslavsky; Dee W West; Robert E Wolf; Martha C Felter; John Z Ayanian Journal: Med Care Date: 2003-09 Impact factor: 2.983
Authors: Christian Passler; Gerhard Prager; Christian Scheuba; Klaus Kaserer; Georg Zettinig; Bruno Niederle Journal: Ann Surg Date: 2003-02 Impact factor: 12.969
Authors: Gregory S Cooper; Beth Virnig; Carrie N Klabunde; Nicola Schussler; Jean Freeman; Joan L Warren Journal: Med Care Date: 2002-08 Impact factor: 2.983
Authors: Beth A Virnig; Joan L Warren; Gregory S Cooper; Carrie N Klabunde; Nicola Schussler; Jean Freeman Journal: Med Care Date: 2002-08 Impact factor: 2.983
Authors: J Kenneth Byrd; Robert J Yawn; Christina S T Wilhoit; Nicoleta D Sora; Linda Meyers; Jyotika Fernandes; Terry Day Journal: Curr Treat Options Oncol Date: 2012-03
Authors: Jonathan R George; Ying C Henderson; Michelle D Williams; Dianna B Roberts; Hu Hei; Stephen Y Lai; Gary L Clayman Journal: J Clin Endocrinol Metab Date: 2015-10-13 Impact factor: 5.958
Authors: Clive S Grant; John M Stulak; Geoffrey B Thompson; Melanie L Richards; Carl C Reading; Ian D Hay Journal: World J Surg Date: 2010-06 Impact factor: 3.352
Authors: Ying C Henderson; Thomas D Shellenberger; Michelle D Williams; Adel K El-Naggar; Mitchell J Fredrick; Kathleen M Cieply; Gary L Clayman Journal: Clin Cancer Res Date: 2009-01-15 Impact factor: 12.531